LTFS
NBIX icon

Ladenburg Thalmann Financial Services’s Neurocrine Biosciences NBIX Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$198K Sell
1,834
-113
-6% -$11.8K ﹤0.01% 2511
2019
Q3 		$175K Sell
1,947
-337
-15% -$31.5K ﹤0.01% 2566
2019
Q2 		$193K Sell
2,284
-147
-6% -$12.1K ﹤0.01% 2497
2019
Q1 		$214K Sell
2,431
-174
-7% -$14.5K ﹤0.01% 2345
2018
Q4 		$186K Buy
2,605
+17
+0.7% +$1.63K ﹤0.01% 2288
2018
Q3 		$319K Buy
2,588
+572
+28% +$64.9K ﹤0.01% 1943
2018
Q2 		$167K Hold
2,016
– – ﹤0.01% 2373
2018
Q1 		$167K Buy
2,016
+1,025
+103% +$86.6K ﹤0.01% 2373
2017
Q4 		$77K Sell
991
-3,188
-76% -$217K ﹤0.01% 2911
2017
Q3 		$256K Buy
4,179
+122
+3% +$6.44K ﹤0.01% 1914
2017
Q2 		$187K Hold
4,057
– – ﹤0.01% 2075
2017
Q1 		$176K Buy
4,057
+3,290
+429% +$141K ﹤0.01% 2005
2016
Q4 		$31K Sell
767
-1,010
-57% -$45.7K ﹤0.01% 3186
2016
Q3 		$90K Buy
1,777
+56
+3% +$2.79K ﹤0.01% 2325
2016
Q2 		$78K Sell
1,721
-55
-3% -$2.53K ﹤0.01% 2338
2016
Q1 		$71K Sell
1,776
-38
-2% -$1.51K ﹤0.01% 2326
2015
Q4 		$103K Sell
1,814
-30
-2% -$1.52K ﹤0.01% 2038
2015
Q3 		$73K Buy
1,844
+1,449
+367% +$70K ﹤0.01% 2211
2015
Q2 		$19K Hold
395
– – ﹤0.01% 3270
2015
Q1 		$15K Buy
395
+35
+10% +$1.25K ﹤0.01% 3369
2014
Q4 		$8K Buy
360
+300
+500% +$5.68K ﹤0.01% 3526
2014
Q3 		$1K Hold
60
– – ﹤0.01% 3809
2014
Q2 		$1K Sell
60
-740
-93% -$10.4K ﹤0.01% 3771
2014
Q1 		$13K Buy
800
+300
+60% +$5.13K ﹤0.01% 2816
2013
Q4 		$5K Buy
+500
New +$4.88K ﹤0.01% 3257
2013
Q3 		– Sell
-400
Closed -$5K – 3776
2013
Q2 		$5K Buy
+400
New +$4.91K ﹤0.01% 3047

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ladenburg Thalmann Financial Services's NBIX Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services reduced its Neurocrine Biosciences (NBIX) stake by 5.8% in Q4 2019, selling an estimated $11.8K and leaving 1,834 shares worth $198K. The position accounts for ﹤0.01% of the portfolio, ranked #2511.

Ladenburg Thalmann Financial Services first reported a position in NBIX in Q2 2013 and has held it in 26 quarters since. The position peaked at $319K in Q3 2018. 391 funds tracked by Wall St. Rank hold NBIX as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 1,834 shares of Neurocrine Biosciences worth $198K as of Q4 2019.
  • Ladenburg Thalmann Financial Services sold 113 Neurocrine Biosciences shares in Q4 2019, an estimated $11.8K.
  • Neurocrine Biosciences made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #2511 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 26 quarters since.
  • Ladenburg Thalmann Financial Services's Neurocrine Biosciences position peaked at $319K in Q3 2018.
  • 391 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.